FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, namely to an antibody to latent TGF-beta 1, a method for production thereof, as well as an immunoconjugate and a composition containing it. Also disclosed is an isolated nucleic acid coding said antibody, as well as a vector and a host cell containing said nucleic acid.
EFFECT: invention is effective for treating fibrosis and cancer.
14 cl, 13 dwg, 7 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO MYOSTATIN, POLYPEPTIDES CONTAINING FC-REGION VARIANTS, AND THEIR APPLICATION METHODS | 2016 |
|
RU2789884C2 |
| ANTIBODIES TO MYOSTATIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2778945C2 |
| ANTIBODIES TO MYOSTATIN, POLYPEPTIDES CONTAINING FC REGION VARIANTS AND METHODS OF THEIR USE | 2015 |
|
RU2799522C2 |
| C5 ANTIBODIES AND THEIR APPLICATION METHODS | 2015 |
|
RU2746356C2 |
| ANTI-CD137 ANTIGEN-BINDING MOLECULES AND USE THEREOF | 2019 |
|
RU2829536C2 |
| ANTIBODIES AGAINST SIGNAL-REGULATORY ALPHA PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2771964C2 |
| ANTI-C5 ANTIBODIES AND METHODS FOR THEIR USE | 2017 |
|
RU2789788C2 |
| MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING SUBSTITUTE FUNCTIONAL ACTIVITY OF BLOOD COAGULATING FACTOR VIII CO-FACTOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SPECIFIED MOLECULE AS ACTIVE INGREDIENT | 2018 |
|
RU2812909C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF THEIR USE | 2019 |
|
RU2800779C2 |
| ANTI-TAU PROTEIN ANTIBODIES AND METHODS OF USING SAID ANTIBODIES | 2016 |
|
RU2732122C2 |
